Personal Profile
Wang Haihe, male, is an introduced talent of Sun Yat-sen University and a professor in the Zhongshan School of Medicine. He obtained his bachelor's degree and master's degree from Northwest A&F University successively from 1990 to 1997. In July 2000, he received his Ph.D. degree from Fujian Agricultural University, under the supervision of Academician Xie Lianhui, a renowned plant pathologist in China. From April 2001 to December 2010, he worked successively as a postdoctoral fellow and a full-time researcher at the National University of Singapore (NUS), Genome Institute of Singapore (GIS), and Institute of Molecular and Cell Biology (IMCB) in Singapore. In January 2011, he returned to China and joined the Zhongshan School of Medicine, Sun Yat-sen University.

Our research team combines mouse tumor models and employs biochemical and molecular biological methods. We were the first to reveal in detail the molecular mechanisms by which the small molecule phosphatase PRL-3 promotes tumorigenesis, metastasis, and drug resistance (Cancer Research, 2006; 2007; iScience, 2020). We were the first to report the unique regulatory mechanism of PRL-3 at the post-transcriptional translational level by polypyrimidine tract-binding protein (PCBP1) (Cancer Cell, 2010), and for the first time confirmed that PCBP1 is a new tumor suppressor gene (Journal of Experimental & Clinical Cancer Research, 2018). We were also the first to identify PRL-3 as an independent prognostic risk factor for FLT3-ITD-negative acute myeloid leukemia (Cancer, 2014). We have conducted extensive basic research on PRL-3 as a biomarker for tumor metastasis and combined basic research with clinical diagnostic applications. In addition, our team has elucidated the mechanism by which mouse SH3BGRL activates the MAPK and PI3K-AKT signaling pathways to promote tumor metastasis. We were the first to discover that human SH3BGRL has an opposite tumor-suppressive effect, while mutated SH3BGRL can promote tumor metastasis like mouse SH3BGRL (Oncogene, 2016) and the mechanism of SH3BGRL-mediated drug resistance in Her2-positive breast cancer (Journal of Experimental & Clinical Cancer Research, 2020). Moreover, we have synthesized and elucidated the mechanism of action of a novel paclitaxel derivative that can overcome the resistance of paclitaxel-resistant cells (Cancer Letters, 2020). We have also achieved outstanding research results in the field of virology (Journal of General Virology, 2 papers in 2004). I have been invited to attend international academic conferences in countries such as the United States, the United Kingdom, Japan, Greece, and Switzerland multiple times and have given invited presentations.

Our research group will apply research methods in molecular biology, biochemistry, cell biology, and proteomics, combined with mouse tumor models, to mainly study the molecular signaling mechanisms by which relevant genes function in tumor occurrence, metastasis, and the differentiation of cancer stem cells during tumor metastasis. This aims to lay a theoretical and practical foundation for the effective diagnosis and treatment of cancer.

Academic Achievements
Academic Works and Textbooks

1. Zhang S, Liu X, Abdulmomen Ali Mohammed S, Li H, Cai W, Guan W, Liu D, Wei Y, Rong D, Fang Y, Haider F, Lv H, Jin Z, Chen X, Mo Z, Li L, Yang S, Wang H. Adaptor SH3BGRL drives autophagy-mediated chemoresistance through promoting PIK3C3 translation and ATG12 stability in breast cancers. Autophagy. 2021 Dec 6:1-19. doi: 10.1080/15548627.2021.2002108. PMID: 34870550. IF=16.016
2.  Zhang S#, Guo X#, Liu X, Zhong Z, Yang S*, Wang H*. Adaptor SH3BGRL promotes breast cancer metastasis through PFN1 degradation by translational STUB1 upregulation. Oncogene. 2021 Jul 30. doi: 10.1038/s41388-021-01970-8. IF=9.867
3. Rong D, Wang C, Zhang X, Wei Y, Zhang M, Liu D, Farhan H, Saleh Abdul M,A, Liu Y, Taouil A, Guo W, Wang Y, Ojima I*, Yang S*, Wang H*. A novel taxane, difluorovinyl-ortataxel, effectively overcomes paclitaxel-resistance in breast cancer cells. Cancer Letters. 2020, doi: https://doi.org/10.1016/j.canlet.2020.06.025. IF=8.679
4. Liu, Y*., Huang, Z., Wei, Y., Zhang M., Li X., Yang S*. and Wang H*. Identification of STXBP6-IRF1 positive feedback loop in regulation of PD-L1 in cancer. Cancer Immunology, Immunotherapy, 2020, 69 (9): https: //doi.org/10.1007/s00262-020-02678-6. IF=6.968
5. Yuan, J., Yu, J., Huang, Y. He, Z., Luo J, Wu Y, Zheng Y, Wu J, Zhu X, Wang H. and Li M*. Antibiotic fidaxomicin is an RdRp inhibitor as a potential new therapeutic agent against Zika virus. BMC Medicine. 2020,18, 204. https://doi.org/10.1186/s12916-020-01663-1. IF=6.782.
6. Li H, Zhang M, Wei Y, Haider F, Lin Y, Guan W, Liu Y, Zhang S, Yuan R, Yang X, Yang S*, Wang H*. SH3BGRL confers innate drug resistance in breast cancer by stabilizing HER2 activation on cell membrane. Journal of Experimental & Clinical Cancer Research, 2020, 39:81. doi:10.1186/s13046-020-01577-z. IF=11.161
7. Zhang M, Wei Y, Liu Y, Guan W, Zhang X, Kong J, Li H, Yang S* and Wang H*. Metastatic phosphatase PRL-3 induces ovarian cancer stem cell sub-population through phosphatase-independent deacetylation modulations. iScience, 2020, 23:100766（1-16）.
8. He K, Wu L, Ding Q, Haider F, Yu H, Wang H*, Xiang G*. Apatinib promotes apoptosis of pancreatic cancer cells through downregulation of hypoxia-inducible factor-1α and increased levels of reactive oxygen species. Oxidative Medicine and Cellular Longevity, 2019, https://doi.org/10.1155/2019/5152072. IF=4.936
9. Gong L, Zhang Q, Pan X, Chen S, Yang L, Liu B, Yang W, Yu L, Xiao Z, Feng X, Wang H, Yuan Z, Peng J, Tan W, Chen J. p53 protects cells from death at the heatstroke threshold temperature. Cell Reports. 2019,29(11):3693-3707. IF=7.815
10. Shi H, Li H, Yuan R, Guan W, Zhang X, Zhang S, Zhang W, Tong F, Li L, Song Z, Wang C, Yang S and Wang H*. PCBP1 depletion promotes tumorigenesis through attenuation of p27Kip1 mRNA stability and translation. Journal of Experimental & Clinical Cancer Research, 2018, 37:187 IF=6.251
11. Xu L, Zhang M, Li H, Guan W, Liu B, Liu F, Wang H, Li J, Yang S, Tong X* & Wang H*  SH3BGRL as a novel prognostic biomarker is down-regulated in acute myeloid leukemia.Leukemia & Lymphoma, 2017, DOI: 10.1080/10428194.2017.1344843
12. Tong F, Guo X, Shi H, Zhang M, Li L, Wang H*, Yang S*. Expression patterns of SH3BGR family members in zebrafish development. Development Genes and Evolution. 2016, 226(4): 287-295.
13. Liu B, Zhang M, Fang T, Yang S and Wang H*. Expression patterns and physiological roles of SH3BGR protein family as adaptor proteins. Integr Cancer Sci Therap, 2016, 3(2): 410-413. Invited review.
14.  Zhang W, Shi H, Zhang M, Liu B, Mao S, Li L, Tong F, Liu G, Yang S, and Wang H*. Poly C binding protein 1 represses autophagy through downregulation of LC3B to promote tumor cell apoptosis in starvation. International Journal of Biochemistry and Cell Biology, 2016,73:127-136. http://dx.doi.org/10.1016/j.biocel. 2016.02.009. 
15. Li L, Shi H, Zhang M, Guo X, Tong Fang, Zhang W, Zhou J, Wang H*, and Yang S*. Upregulation of metastasis-associated PRL-3 initiates chordoma in zebrafish. International Journal of Oncology，2016, 48（4）1541-1552.  
16. Wang H*, Liu B, Al-aidaroos AQ, Li L, Shi H, Guo K, Li J, Tan JP, Loo JM, Liu B, Shi H, and Zeng Q.  Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans. Oncogene，2016, 35 (25): 3303-3313. IF=8.456
17. Dong Q, Ding X, Chang B, Wang H, Wang A. PRL-3 promotes migration and invasion and is associated with poor prognosis in salivary adenoid cystic carcinoma. J Oral Pathol Med. 2015 Jun 3. doi: 10.1111/jop.12331. 
18. Chen Y, Pei H, Chang Y, Chen M, Wang H, Xie H and Yao S*. The impact of endometrioma and laparoscopic cystectomy on ovarian reserve and the exploration of related factors assessed by serum anti-Mullerian hormone: a prospective cohort study. Journal of Ovarian Research, 2014, 7:108
19. Qu S, Liu B,Guo X, Shi H, Zhou M, Li L, Yang S, Tong X* and Wang H*. Independent oncogenic and therapeutic significance of phosphatase PRL-3 in FLT3-ITD negative acute myeloid leukemia. Cancer, 2014,120:2130-2141. IF=5.201 
20. Liu H, Al-aidaroos AQ, Wang H, Guo K, Li J, Zhang F and Zeng Q. PRL-3 suppresses c-Fos and integrin alpha2 expression in ovarian cancer cells. BMC Cancer. 2013. 13:80. doi:10.1186/1471-2407-13-80.
21. Wang H., Vardy Leah , Tan Cheng Peow, Loo Jia Min, Guo Ke, Li Jie, Lim Seng Gee, Zhou Jianbiao, Chng Wee Joo, Ng Siok Bian, Li Hui Xiang and Zeng Qi. PCBP1 suppresses the translation of metastasis-associated PRL-3 phosphatase. Cancer Cell, 2010,18:52-62. 
22. Wang H. Quah Yi Ling, Samatha, Dong Jing Ming, Manser E., Tang Jing Ping, Zeng Qi. 2007. PRL-3 downregulates PTEN expression and signals through PI3K to promote epithelial-mensenchymal transition. Cancer Res. 67 (7): 2922-2926. 
23. Guo K., Li, J., Wang H., Osato M., Tang JP., Quah S., Gan B, and Zeng Q. PRL-3 initiates tumor angiogenesis by recruiting endothelial cells in vitro and in vivo. Cancer Res. 2006, 66: 9625-9635. 
24. Cao S. S., Wang H, Luhur A., and Wong S.M. Yeast expression and characterization of SARS-CoV N protein.  Journal of Virological Methods, 2005,130: 83-88. 
25. Wang H.,Yu H, and S. M. Wong. . Mutation of Phe 50 to Ser 50 in the 126/183 Kilodalton proteins of Odontoglossum ringspot virusabolishes virus replication but can be restored by reversion. Journal of General Virology, 2004, 85: 2447-2457. 
26. Wang H and S. M. Wong. Significance of 3’-terminal region in minus-strand synthesis of Hibiscus chlorotic ringspot virus. Journal of General Virology, 2004, 85: 1763-1776.

Research Projects

• ​National Natural Science Foundation of China:
  • Project Approval Number: 81672704, Duration: 2017 - 2020; Principal Investigator; Direct Funding: 580,000 yuan.
  • Project Approval Number: 81472730, Duration: 2015 - 2018; Principal Investigator; Funding: 720,000 yuan.
  • Project Approval Number: 31271481, Duration: 2013 - 2016; Principal Investigator; Funding: 800,000 yuan.
  • Project Approval Number: 81171947, Duration: 2012 - 2015; Principal Investigator; Funding: 600,000 yuan.
• ​Guangdong Provincial Science and Technology Plan:
  • Project Approval Number: 2015B020211012, Duration: 2015.10 - 2017.12; Co-Principal Investigator; Funding: 1,000,000 yuan.
  • Guangdong Provincial Natural Science Foundation International Cooperation Project:
    • Project Approval Number: 2014A050503030, Duration: 2016.01 - 2018.12; Principal Investigator; Funding: 500,000 yuan.
• ​Guangzhou Science and Technology Plan:
  • Project Approval Number: 201607010223, Duration: 2016 - 2018; Principal Investigator; Funding: 200,000 yuan.
• ​Innovation Project of Guangdong Provincial Department of Education:
  • Project Number: 2012KJCX0002, Duration: 2013 - 2014; Principal Investigator; Funding: 60,000 yuan.
• ​Sun Yat-sen University Startup Fund: Duration: 2011 - 2012; Principal Investigator; Funding: 800,000 yuan.

Academic Affiliations
Member of the European Society for Medical Oncology (ESMO member, ID 501195)